Peptides DB
Research-centric peptide and protocol reference hub

Desmopressin record · updated 6h ago

Sleep & circadianNeuro & moodGrade A · human clinicalResearch use only
All 17 studiesJump to the evidenceCompare
What is Desmopressin used for?

Research peptide discovered via AI researcher. peptide-based therapeutic

How it works: V2 receptor agonist

Primarily researched for · Sleep & circadianRoute · Intranasal, Subcutaneous injection, Oral

Development stage

where Desmopressin sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Cleared
    Phase 3
    Confirmatory trials
  5. 5Current
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 91 registered trials. It describes the research record, not a recommendation.

Identity
NameDesmopressin
Chain length—
Molecular weight1,069.2 Da
FormulaC46H64N14O12S2
Structure typeNot established
ClassHealing
Research levelFDA Approved
Discovered byThe Librarian · 2026

Mass and formula from PubChem CID 5311065. No verified residue count for this compound.

Pharmacology
MechanismV2 receptor agonist
RouteIntranasal, Subcutaneous injection, Oral
Half-life~3-4 hours
Time to peak0.5-1 hour
Duration6-8 hours
Extraction confidence0.90
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Sep 7, 2026. How this works →
Research stats
Total studies17
Human / animal / cellular12 / 1 / 0
Highest trial phasePhase 4
Years covered2023–2026
Latest study15d ago
Publication history
20232026
Research funding
51 NIH projects · $12.3M awarded · through FY2025
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reports3,678
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

17 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
Multifocal intracranial hemorrhage on emergency brain CT in a child with end-stage nephrotic syndrome.
FindingNot reported in abstract.
Human2026Full text read0.80
Ginkgo biloba versus desmopressin in treatment of children with monosymptomatic nocturnal enuresis: A randomized controlled trial.
FindingMedian wet nights per week after 3 months: combination group 0 [IQR 0-2], GBE 6 [0.5-6.5], Desmopressin 2 [0-6], p<0.001.
Human2026Full text read0.80
Evaluation of Ease of Use for Pediatric Medications Requiring Decapsulation, Dissolution, or Partial Dosing: A Questionnaire-Based Study in Japan.
FindingNot reported in abstract.
Human2026Full text read0.80
Von Willebrand Disease Type 2A: An Update.
TakeawayThis review offers an updated synthesis of Type 2A von Willebrand Disease, focusing on its pathophysiology and management but lacks new experimental insights.
review2026Full text read0.90
Efficacy and safety of first-line therapies and first-line-based combination therapies for monosymptomatic nocturnal enuresis in children: a network meta-analysis.
FindingDesmopressin plus oxybutynin, tolterodine, or solifenacin significantly improved CR compared to desmopressin monotherapy.
review2026Full text read0.90
Consensus Recommendations for the Clinical Management of Wolfram syndrome Using a Delphi Method
Finding35 final consensus statements reached ≥80% agreement.
review2026Full text read0.70
Open-Label, Balanced, Randomized, Single-Dose, Three-Treatment, Three-Sequence, Three-Period, Three-Way Crossover Oral Bioequivalence Study of Desmopressin Acetate Oral Solution.
FindingGeometric mean ratio of 101.9% (93.9%-110.5%) for Cmax.
Human2023Full text read0.90
AVP Deficiency Following 9-valent HPV Vaccination: A Case Report
FindingNot reported in abstract.
Human2026Full text read0.80
Renal water handling at early stages of autosomal dominant polycystic kidney disease
FindingNot reported in abstract.
Human2026Full text read0.80
Polyuria and Hypokalemia in an Adolescent: Deciphering the Dual Tubulopathy of Primary Sjögren’s Syndrome
FindingUrine osmolality remained below 150 mOsm/kg after desmopressin.
Human2026Full text read0.80
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials.
TakeawayNot reported in abstract.
—2026Title only0.10
Clinical and diagnostic complexities of adipsic arginine vasopressin deficiency.
Finding320 mOsm/kg plasma osmolality.
Human2026Full text read0.80

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching Desmopressin will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much Desmopressin is discussed should be drawn from it.